Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Capricor Therapeutics, Inc. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026. The complaint claims defendants made false and misleading statements and failed to disclose that Capricor changed the pre-specified statistical analysis plan for Deramiocel without FDA agreement, creating a significant risk the FDA would find insufficient evidence of effectiveness and deny approval for Duchenne muscular dystrophy. Investors have until September 28, 2026 to seek lead plaintiff appointment. The firm represents investors on a contingency fee basis.
Capricor Therapeutics IncClass action lawsuit alleges securities law violations and FDA approval risk for Deramiocel.